S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:INO - Inovio Pharmaceuticals Stock Price, Forecast & News

$8.02
-0.30 (-3.61 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$7.60
Now: $8.02
$9.32
50-Day Range
$3.19
MA: $5.98
$14.09
52-Week Range
$1.91
Now: $8.02
$19.36
Volume31.26 million shs
Average Volume28.45 million shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Read More
Inovio Pharmaceuticals logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INO
CUSIPN/A
Phone267-440-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.11 million
Book Value$0.05 per share

Profitability

Net Income$-119,360,000.00
Net Margins-2,901.99%

Miscellaneous

Employees281
Market Cap$1.17 billion
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.


Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

How has Inovio Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INO shares have decreased by 4.2% and is now trading at $8.02. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Inovio Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Inovio Pharmaceuticals.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Inovio Pharmaceuticals.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals Inc (NASDAQ:INO) posted its quarterly earnings results on Thursday, March, 12th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.14. The biopharmaceutical company earned $0.28 million during the quarter, compared to the consensus estimate of $1.36 million. Inovio Pharmaceuticals had a negative return on equity of 259.07% and a negative net margin of 2,901.99%. During the same period in the previous year, the firm earned ($0.35) earnings per share. View Inovio Pharmaceuticals' earnings history.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

9 equities research analysts have issued 1-year target prices for Inovio Pharmaceuticals' shares. Their forecasts range from $4.00 to $13.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price. View analysts' price targets for Inovio Pharmaceuticals.

What are Wall Street analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "We are maintaining our Buy rating of EDAP TMS and our 12-month price target of $6.50 per diluted ADS. We derived our price target based on the average of two valuation methods: 1) price-earnings multiple using 25x 2026 EPS estimate discounted at 12%; and 2) discounted cash flow analysis using a 2% terminal growth rate and discounting 2026 free cash flow estimate at a 12% discount rate. (1) commercial; (2) regulatory; (3) currency; (4) reimbursement; and (5) intellectual property." (6/11/2019)
  • 2. According to Zacks Investment Research, "Inovio’s earnings and revenues missed estimates in the first quarter of 2019. The company’s progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Apart from VGX-3100, Inovio also has some promising vaccine candidates in its portfolio, which are progressing well. Additionally, Inovio has collaboration with big pharma companies like Roche, Regeneron and AstraZeneca, which helps the company with their expertise for further growth. Moreover, the company’s targeted cervical cancer market holds untapped potential. However, the company has no approved product in its portfolio and its excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Shares have underperformed the industry year to date." (5/28/2019)
  • 3. Maxim Group analysts commented, "Inovio and its collaborators from The Wistar Institute presented positive preclinical data from its novel dBiTE (DNA-Encoded Bi-specific T Cell Engager) program at the American Association for Cancer Research (AACR) annual meeting." (4/3/2019)

Has Inovio Pharmaceuticals been receiving favorable news coverage?

News coverage about INO stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future. View the latest news aboutInovio Pharmaceuticals.

Are investors shorting Inovio Pharmaceuticals?

Inovio Pharmaceuticals saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 16,140,000 shares, an increase of 24.1% from the February 13th total of 13,010,000 shares. Based on an average daily trading volume, of 19,430,000 shares, the days-to-cover ratio is currently 0.8 days. Approximately 16.6% of the company's stock are sold short. View Inovio Pharmaceuticals' Current Options Chain.

Who are some of Inovio Pharmaceuticals' key competitors?

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Anavex Life Sciences (AVXL), Opko Health (OPK), Sonoma Pharmaceuticals (SNOA), Advanced Micro Devices (AMD), Novavax (NVAX), Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), WPX Energy (WPX) and POET Technologies (POETF).

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:
  • Dr. J. Joseph Kim, CEO, Pres & Director (Age 50)
  • Mr. Peter D. Kies, Chief Financial Officer (Age 56)
  • Dr. Jacqueline E. Shea, COO & Exec. VP (Age 53)
  • Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 58)
  • Dr. Laurent M. Humeau, Chief Scientific Officer & Exec. VP (Age 52)

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (4.98%), Sumitomo Mitsui Trust Holdings Inc. (5.05%), ARK Investment Management LLC (4.58%), State Street Corp (1.56%), Geode Capital Management LLC (1.33%) and Jacobs Levy Equity Management Inc. (0.92%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau, Peter Kies and Simon X Benito. View institutional ownership trends for Inovio Pharmaceuticals.

Which institutional investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Nuveen Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., TIAA FSB, Bank of New York Mellon Corp, Defender Capital LLC., and Bank of America Corp DE. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, and Jong Joseph Kim. View insider buying and selling activity for Inovio Pharmaceuticals.

Which institutional investors are buying Inovio Pharmaceuticals stock?

INO stock was purchased by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., ARK Investment Management LLC, Renaissance Technologies LLC, California Public Employees Retirement System, Goldman Sachs Group Inc., Geode Capital Management LLC, UBS Group AG, and Barclays PLC. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim, and Laurent Humeau. View insider buying and selling activity for Inovio Pharmaceuticals.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $8.02.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $1.17 billion and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-119,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe. View additional information about Inovio Pharmaceuticals.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is http://www.inovio.com/.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 92121. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]


MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  654 (Vote Outperform)
Underperform Votes:  422 (Vote Underperform)
Total Votes:  1,076
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel